Category Archives: ALS Treatment

NEW YORK, May 5, 2020 /PRNewswire/ --Today, Target ALS and The Association for Frontotemporal Degeneration (AFTD) announced $5 million in funding awards for work by six research teams to aid in the discovery of biomarkers and viable treatments for ALS and frontotemporal degeneration (FTD). ALS and FTD (the most common dementia under 60) overlap in genetic causes and biological mechanisms. By joining forces, Target ALS and AFTD are leveraging the combined expertise of researchers in two fields, fueling collaboration in support of the most promising ideas Continue reading →

JERSEY CITY, N.J., May 5, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the treatment with RADICAVA (edaravone) in North America since the therapy was approved by the U.S. Food and Drug Administration (FDA) on May 5, 2017. Continue reading →

TORONTO, April 29, 2020 /CNW/ -Mitsubishi Tanabe Pharma CorporationCanada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA (edaravone) is now listed on the Rgie de l'assurance maladie du Qubec (RAMQ) formulary (special authorization). Continue reading →

Dr. Disneys research confronts diseases that include Alzheimers, ALS, muscular dystrophy and, recently, the coronavirus. JUPITER A scientist at Scripps Research Institute studying brain diseases and the novel coronavirus has received a hefty grant from the National Institute of Neurological Disorders and Stroke. Continue reading →

A year ago, Chad McBride was the chair of the communications studies department at Creighton University in Omaha, Nebraska. He and his husband, Allen Saunders, were raising their 3-year-old son, Jackson, in a close-knit community of friends, neighbours, and colleagues. [Life] was beyond magical, McBride, 44, told Insider. Continue reading →

An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. Continue reading →

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines Continue reading →

GREENVILLE, N.C., March 25, 2020 /PRNewswire/ --Robert C. Continue reading →

"What BL-001 attempts to do is to modify the microorganisms in the stomach to restore the GABA and glutamate levels that are disrupted in the brains of people living with ALS," said Kuldip Dave, Ph.D., vice president of research at The ALS Association. "It's a fascinating approach to using the body's own protective bacteria to reset dysfunctional neurotransmitters that lead to loss of motor control." "We are witnessing incredible innovation in the field of microbiota-based therapeutics and research," said Bloom's CEO Christopher Reyes, PhD Continue reading →

Elon Musk has opened up about contracting malaria in 2000, saying he had a "near fatal case" of the disease. In several tweets on Monday night, the Tesla and SpaceX CEO described what happened when he contracted falciparum, a potentially fatal form of malaria that can affect the central nervous system or cause "acute respiratory distress," according to the Centers for Disease Control and Prevention. Continue reading →